Join to View Full Profile
601 Crittenden BlvdRochester, NY 14642
Phone+1 585-275-5823
Dr. Mulkerin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Daniel Mulkerin, MD, is an oncologist based in Rochester, NY, specializing in gastrointestinal cancer and hematologic oncology. He completed his medical education at Sidney Kimmel Medical College, followed by a residency in internal medicine and a fellowship in medical oncology at the University of Wisconsin Hospitals and Clinics. Dr. Mulkerin served as the Medical Director at UW Health from 1999 to 2021. His experience includes expertise in hereditary nonpolyposis colon cancer and gastrointestinal oncology. He has contributed to multiple publications, including work on mismatch repair and microsatellite testing in colorectal cancer, and has been involved in clinical trials for treatments involving anal and metastatic colorectal cancer, among others.
Education & Training
University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 1996 - 1999- University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1992 - 1996
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1992
Certifications & Licensure
WI State Medical License 1993 - 2027
NY State Medical License 2021 - 2026
IL State Medical License 2014 - 2017
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction Start of enrollment: 2003 Jan 01
- Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancer Start of enrollment: 2004 Apr 01
- Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer Start of enrollment: 2000 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- GABAergic signaling contributes to tumor cell invasion and poor overall survival in colorectal cancer.Carly Strelez, Francesca Battaglin, Rachel Perez, Yan Yang, Christopher Cherry
Oncogene. 2025-10-01 - 1 citationsSubclonal response heterogeneity to define cancer organoid therapeutic sensitivity.Jeremy D Kratz, Shujah Rehman, Katherine A Johnson, Amani A Gillette, Aishwarya Sunil
Scientific Reports. 2025-04-09 - 2 citationsMismatch Repair and Microsatellite Testing for Individuals With Colorectal Cancer.Totadri Dhimal, Fernando Colugnati, Bailey K Hilty Chu, Anthony Loria, Paula Cupertino
JAMA Oncology. 2024-11-01
Press Mentions
Wilmot Cancer Institute Welcomes Leading Rochester Breast Cancer Surgeon Lori Medeiros, MDFebruary 28th, 2025- Wilmot Cancer Institute Brings Multidisciplinary Cancer Care to WebsterJuly 7th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
